AstraZeneca and Sanofi announced that their MELODY Phase III trial of nirsevimab hit the primary endpoint in medically attended lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) in healthy late preterm and term infants. RSV infections cause about 80,000 hospitalizations in children and 500 deaths each year. 

A Maryland-based biotech company believes it can solve a riddle that has baffled Big Pharma for decades: how to protect against a virus that infects almost every American child. If mid-stage trial data proves positive, Novavax Inc will be closer than any drug developer to a vaccine for respiratory syncytial virus, or RSV, which affects […]